{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T22:18:30Z","timestamp":1794435510430,"version":"4.9.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pulmonary delivery of mRNA via inhalation is a very attractive approach for RNA-based therapy for treatment of lung diseases. In this work, we have demonstrated successful development of an mRNA-lipid nanoparticle (LNP) dry powder product (DPP), wherein the LNPs were spray dried using hydroalcoholic solvent along with mannitol and leucine as excipients. The desired critical attributes for the DPP were accomplished by varying the excipients, lipid composition, concentration of LNPs, and weight percentage of mRNA. Leucine alone or in combination with mannitol improved the formulation by increasing the mRNA yield as well as decreasing the particle size. Intratracheal administration of the DPP in mice resulted in luciferase expression in the trachea and lungs indicating successful delivery of functional mRNA. Our results show formulation optimization of mRNA LNPs administered in the form of DPP results in an efficacious functional delivery with great promise for future development of mRNA therapeutics for lung diseases.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s13346-023-01402-y","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T10:01:56Z","timestamp":1690884116000},"page":"360-372","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Inhalable dry powder product (DPP) of mRNA lipid nanoparticles (LNPs) for pulmonary delivery"],"prefix":"10.1007","volume":"14","author":[{"given":"Ashish","family":"Sarode","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Vargas-Montoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayed","family":"Allawzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa","family":"Zhilin-Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saswata","family":"Karmakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne","family":"Boeglin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfeng","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9433-3089","authenticated-orcid":false,"given":"Shrirang","family":"Karve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"DeRosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"key":"1402_CR1","doi-asserted-by":"crossref","unstructured":"Schoenmaker L, Witzigmann D, Kulkarni JA, Verbeke R, Kersten G, Jiskoot W, et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J Pharmaceut [Internet]. 2021;601:120586. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33839230","DOI":"10.1016\/j.ijpharm.2021.120586"},{"key":"1402_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines \u2014 a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261\u201379.","journal-title":"Nat Rev Drug Discov"},{"key":"1402_CR3","first-page":"147","volume":"9","author":"E Bettini","year":"2021","unstructured":"Bettini E, Locci M. SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond. Nato Adv Sci Inst Se. 2021;9:147.","journal-title":"Nato Adv Sci Inst Se"},{"key":"1402_CR4","doi-asserted-by":"crossref","unstructured":"Bhat B, Karve S, Anderson DG. mRNA therapeutics: beyond vaccine applications. Trends Mol Med [Internet]. 2021;27:923\u20134. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34172390","DOI":"10.1016\/j.molmed.2021.05.004"},{"key":"1402_CR5","first-page":"1042","volume":"12","author":"H Zhang","year":"2020","unstructured":"Zhang H, Leal J, Soto MR, Smyth HDC, Ghosh D. Aerosolizable lipid nanoparticles for pulmonary delivery of mRNA through design of experiments. Pharm. 2020;12:1042.","journal-title":"Pharm"},{"key":"1402_CR6","doi-asserted-by":"crossref","unstructured":"Trepotec Z, Lichtenegger E, Plank C, Aneja MK, Rudolph C. Delivery of mRNA Therapeutics for the treatment of hepatic diseases. Mol Ther [Internet]. 2019;27:794\u2013802. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30655211","DOI":"10.1016\/j.ymthe.2018.12.012"},{"key":"1402_CR7","doi-asserted-by":"crossref","unstructured":"Sahu I, Haque A, Weidensee B, Weinmann P, Kormann MSD. Recent developments in mRNA-based protein supplementation therapy to target lung diseases. Mol Ther [Internet]. 2019;27:803\u201323. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30905577","DOI":"10.1016\/j.ymthe.2019.02.019"},{"key":"1402_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jconrel.2019.10.026","volume":"314","author":"Y Qiu","year":"2019","unstructured":"Qiu Y, Man RCH, Liao Q, Kung KLK, Chow MYT, Lam JKW. Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide. J Control Release. 2019;314:102\u201315.","journal-title":"J Control Release"},{"key":"1402_CR9","doi-asserted-by":"crossref","unstructured":"Feldmann DP, Merkel OM. The advantages of pulmonary delivery of therapeutic siRNA. Ther Deliv [Internet]. 2015;6:407\u20139. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25996039","DOI":"10.4155\/tde.15.8"},{"key":"1402_CR10","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/s41587-020-0692-z","volume":"38","author":"C Shaffer","year":"2020","unstructured":"Shaffer C. Mist begins to clear for lung delivery of RNA. Nat Biotechnol. 2020;38:1110\u20132.","journal-title":"Nat Biotechnol"},{"key":"1402_CR11","doi-asserted-by":"crossref","unstructured":"Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharmaceut [Internet]. 2010;392:1\u201319. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20223286","DOI":"10.1016\/j.ijpharm.2010.03.017"},{"key":"1402_CR12","doi-asserted-by":"crossref","unstructured":"Miwata K, Okamoto H, Nakashima T, Ihara D, Horimasu Y, Masuda T, et al. Intratracheal administration of siRNA dry powder targeting vascular endothelial growth factor inhibits lung tumor growth in mice. Mol Ther - Nucleic Acids [Internet]. 2018;12:698\u2013706. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30092405","DOI":"10.1016\/j.omtn.2018.07.009"},{"key":"1402_CR13","doi-asserted-by":"crossref","unstructured":"Birchall JC, Kellaway IW, Gumbleton M. Physical stability and in-vitro gene expression efficiency of nebulised lipid-peptide-DNA complexes. Int J Pharmaceut [Internet]. 2000;197:221\u201331. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10704809","DOI":"10.1016\/S0378-5173(00)00339-2"},{"key":"1402_CR14","doi-asserted-by":"crossref","unstructured":"Lokugamage MP, Vanover D, Beyersdorf J, Hatit MZC, Rotolo L, Echeverri ES, et al. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs. Nat Biomed Eng [Internet]. 2021;5:1059\u201368. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34616046","DOI":"10.1038\/s41551-021-00786-x"},{"key":"1402_CR15","doi-asserted-by":"crossref","unstructured":"Roche N, Dekhuijzen PN. The evolution of pressurized metered-dose inhalers from early to modern devices. J Aerosol Med Pulm D [Internet]. 2016;29:311\u201327. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26824873","DOI":"10.1089\/jamp.2015.1232"},{"key":"1402_CR16","doi-asserted-by":"crossref","unstructured":"Zara DL, Sun F, Zhang F, Franek F, Sivars KB, Horndahl J, et al. Controlled pulmonary delivery of carrier-free budesonide dry powder by atomic layer deposition. Acs Nano [Internet]. 2021;15:6684\u201398. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33769805","DOI":"10.1021\/acsnano.0c10040"},{"key":"1402_CR17","doi-asserted-by":"crossref","unstructured":"Lam JK, Liang W, Chan HK. Pulmonary delivery of therapeutic siRNA. Adv Drug Deliver Rev [Internet]. 2012;64:1\u201315. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21356260","DOI":"10.1016\/j.addr.2011.02.006"},{"key":"1402_CR18","doi-asserted-by":"crossref","unstructured":"Boer AH de, Hagedoorn P, Hoppentocht M, Buttini F, Grasmeijer F, Frijlink HW. Dry powder inhalation: past, present and future. Expert Opin Drug Del [Internet]. 2017;14:499\u2013512. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27534768","DOI":"10.1080\/17425247.2016.1224846"},{"key":"1402_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2013.11.005","volume":"86","author":"S Claus","year":"2014","unstructured":"Claus S, Weiler C, Schiewe J, Friess W. How can we bring high drug doses to the lung? Eur J Pharm Biopharm. 2014;86:1\u20136.","journal-title":"Eur J Pharm Biopharm"},{"key":"1402_CR20","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.drudis.2013.11.013","volume":"19","author":"Y Rahimpour","year":"2014","unstructured":"Rahimpour Y, Kouhsoltani M, Hamishehkar H. Alternative carriers in dry powder inhaler formulations. Drug Discov Today. 2014;19:618\u201326.","journal-title":"Drug Discov Today"},{"key":"1402_CR21","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S1461-5347(98)00099-6","volume":"1","author":"RJ Malcolmson","year":"1998","unstructured":"Malcolmson RJ, Embleton JK. Dry powder formulations for pulmonary delivery. Pharm Sci Technol To. 1998;1:394\u20138.","journal-title":"Pharm Sci Technol To"},{"key":"1402_CR22","doi-asserted-by":"crossref","unstructured":"Chow MY, Lam JK. Dry powder formulation of plasmid DNA and siRNA for inhalation. Curr Pharm Design [Internet]. 2015;21:3854\u201366. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26290202","DOI":"10.2174\/1381612821666150820105916"},{"key":"1402_CR23","doi-asserted-by":"crossref","unstructured":"Keil TW, Merkel OM. Dry powder inhalation of siRNA. Ther Deliv [Internet]. 2019;10:265\u20137. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31094296","DOI":"10.4155\/tde-2019-0018"},{"key":"1402_CR24","doi-asserted-by":"crossref","unstructured":"Demoly P, Hagedoorn P, Boer AH de, Frijlink HW. The clinical relevance of dry powder inhaler performance for drug delivery. Resp Med [Internet]. 2014;108:1195\u2013203. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24929253","DOI":"10.1016\/j.rmed.2014.05.009"},{"key":"1402_CR25","doi-asserted-by":"crossref","unstructured":"Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Resp Crit Care [Internet]. 2005;172:1497\u2013504. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16192448","DOI":"10.1164\/rccm.200410-1414OC"},{"key":"1402_CR26","doi-asserted-by":"crossref","unstructured":"Lechuga-Ballesteros D, Charan C, Stults CL, Stevenson CL, Miller DP, Vehring R, et al. Trileucine improves aerosol performance and stability of spray-dried powders for inhalation. J Pharm Sci [Internet]. 2008;97:287\u2013302. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17823950","DOI":"10.1002\/jps.21078"},{"key":"1402_CR27","doi-asserted-by":"crossref","unstructured":"Sosnik A, Seremeta KP. Advantages and challenges of the spray-drying technology for the production of pure drug particles and drug-loaded polymeric carriers. Adv Colloid Interfac [Internet]. 2015;223:40\u201354. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26043877","DOI":"10.1016\/j.cis.2015.05.003"},{"key":"1402_CR28","doi-asserted-by":"crossref","unstructured":"Shetty N, Park H, Zemlyanov D, Mangal S, Bhujbal S, Zhou QT. Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation. Int J Pharmaceut [Internet]. 2018;544:222\u201334. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29678544","DOI":"10.1016\/j.ijpharm.2018.04.034"},{"key":"1402_CR29","doi-asserted-by":"crossref","unstructured":"Chew NY, Shekunov BY, Tong HH, Chow AH, Savage C, Wu J, et al. Effect of amino acids on the dispersion of disodium cromoglycate powders. J Pharm Sci [Internet]. 2005;94:2289\u2013300. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16136546","DOI":"10.1002\/jps.20426"},{"key":"1402_CR30","doi-asserted-by":"crossref","unstructured":"Popowski KD, Moatti A, Scull G, Silkstone D, Lutz H, Abad BL de J, et al. Inhalable dry powder mRNA vaccines based on extracellular vesicles. Matter. 2022;5:2960\u201374.","DOI":"10.1016\/j.matt.2022.06.012"},{"key":"1402_CR31","unstructured":"Karve S, DeRosa F, Heartin M, Patel Z, Sarode A. Dry powder formulations for messenger rna. US 2020\/0022921. 2022."},{"key":"1402_CR32","unstructured":"Karve S, DeRosa F, Wangweerawong A, Karmakar S. Phenolic acid lipid based cationic lipids. WO 2021\/202694 A1. 2021"},{"key":"1402_CR33","unstructured":"Karve S, DeRosa F. Tricine and citric acid lipids. WO2020\/257716 A1. 2020"},{"key":"1402_CR34","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ymthe.2019.03.001","volume":"27","author":"F DeRosa","year":"2019","unstructured":"DeRosa F, Smith L, Shen Y, Huang Y, Pan J, Xie H, et al. Improved efficacy in a Fabry disease model using a systemic mRNA liver depot system as compared to enzyme replacement therapy. Mol Ther. 2019;27:878\u201389.","journal-title":"Mol Ther"},{"key":"1402_CR35","doi-asserted-by":"publisher","first-page":"20340","DOI":"10.3390\/ijms141020340","volume":"14","author":"AP Siegel","year":"2013","unstructured":"Siegel AP, Baird MA, Davidson MW, Day RN. Strengths and weaknesses of recently engineered red fluorescent proteins evaluated in live cells using fluorescence correlation spectroscopy. Int J Mol Sci. 2013;14:20340\u201358.","journal-title":"Int J Mol Sci"},{"key":"1402_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2022.102134","volume":"75","author":"CJ Woo","year":"2022","unstructured":"Woo CJ, Allawzi A, Clark N, Kaushal N, Efthymiou T, Thamsen M, et al. Inhaled delivery of a lipid nanoparticle encapsulated messenger RNA encoding a ciliary protein for the treatment of primary ciliary dyskinesia. Pulm Pharmacol Ther. 2022;75: 102134.","journal-title":"Pulm Pharmacol Ther"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-023-01402-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-023-01402-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-023-01402-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T10:26:47Z","timestamp":1704191207000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-023-01402-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1402"],"URL":"https:\/\/doi.org\/10.1007\/s13346-023-01402-y","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,1]]},"assertion":[{"value":"25 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal protocols were approved by the Institutional Animal Care and Use Committees (IACUCs) of the facilities at Alpha Preclinical (North Grafton, MA) and Biomere (Worcester, MA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors have given approval to the final version of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered potential competing interests: Ashish Sarode, Priyal Patel, Natalia Vargas-Montoya, Ayed Allawzi, Alisa Zhilin-Roth, Saswata Karmakar, Lianne Boeglin, Hongfeng Deng, Shrirang Karve, and Frank DeRosa are current or former employees of Sanofi and may hold stock in Sanofi company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}